A Multi-site study of Tamoxifen dose escalation study in breast cancer patients with CYP2D6 polymorphisms (TADE study)

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1031982

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Tamoxifen is a selective anti-oestrogenic medication commonly used to treat breast cancer. Recent evidence suggests that tamoxifen may not be adequately activated in the body of some people because of their genetic make-up, and that this may reduce its effectiveness. In this study of 120 women, we will determine whether increasing tamoxifen dosage is a useful strategy in people with low activation levels. This could provide practical guidance for patients and clinicians managing breast cancer.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2016

Funding Scheme: Project Grants

Funding Amount: $340,768.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

breast cancer | cytochrome P450 | drug metabolism | pharmacogenomics | phenotype-genotype correlation | tamoxifen | therapeutic drug monitoring

Related Links